Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739789 | 1.00 | PTGS1 (0.38) | PTGS1PTGS2 | |
| SCHEMBL16734811 | 0.82 | CA1 (0.36) | PTGS1 | |
| SCHEMBL1627257 | 0.78 | CA1 (0.48) | PTGS1PTGS2 | |
| SCHEMBL3953597 | 0.78 | CA1 (0.48) | PTGS1PTGS2 | |
| SCHEMBL1990366 | 0.77 | NFE2L2 (0.41) | PTGS1PTGS2 | |
| Boric Acid SCHEMBL28062333 | 0.76 | PTGS1 (0.39) | PTGS1PTGS2 | |
| SCHEMBL19665083 | 0.75 | CA1 (0.36) | — | |
| SCHEMBL16399191 | 0.75 | NFE2L2 (0.47) | — | |
| SCHEMBL27917015 | 0.73 | PTGS1 (0.42) | PTGS1PTGS2 | |
| SCHEMBL14740133 | 0.73 | ALOX5 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12512511-B2 | Solid electrolyte including polymer containing boron and fluorine structure, preparation method, and lithium ion battery including the same | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20220328874-A1 | SOLID POLYMER ELECTROLYTE CONTAINING BORON AND FLUORINE STRUCTURES, AND PREPARATION METHOD AND APPLICATION THEREOF | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| EP-4068453-A1 | SOLID-STATE POLYMER ELECTROLYTE CONTAINING BORON-FLUORINE STRUCTURE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Zhuhai CosMX Battery Co., Ltd. (CN) | 2022-10-05 | — | — | EP | disclosed |
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2022-02-17 | — | — | US | disclosed |
| US-20200352898-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2020-11-12 | — | — | US | disclosed |
| US-RE48301-E1 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-11-10 | — | — | US | disclosed |
| US-20190029990-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2019-01-31 | — | — | US | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| US-20170165219-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORP (FI) | 2017-06-15 | — | — | US | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-20150218124-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2015-08-06 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2855426-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | Orion Corporation (FI) | 2015-04-08 | — | — | EP | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2013175053-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | ORION CORPORATION (FI) | 2013-11-28 | — | — | WO | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590980-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004373-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165219-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | PTGS1 961/4885PTGS2 1655/4885 |
| US-20200352898-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | PTGS1 961/4885PTGS2 1655/4885 |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | PTGS1 1978/4885PTGS2 3284/4885 |
| US-20190029990-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | PTGS1 961/4885PTGS2 1655/4885 |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | PTGS1 610/4885PTGS2 1247/4885 |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | PTGS1 1978/4885PTGS2 3284/4885 |
| US-12512511-B2 | Solid electrolyte including polymer containing boron and fluorine structure, preparation method, and lithium ion battery including the same | SCN2B, VMP1, BRD9 | PTGS1 4781/4885PTGS2 4742/4885 |
| US-20150218124-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | PTGS1 961/4885PTGS2 1655/4885 |
| US-20220047540-A1 | CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS | COMT, PNMT, HNMT | PTGS1 961/4885PTGS2 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.